Arsalan Mani, Khan Samir, Golman Jake, Szerlip Molly, Mahoney Cecile, Herbert Morley, Brown David, Mack Michael, Holper Elizabeth M
Kerckhoff Klinik, Bad Nauheim, Germany.
Baylor Research Institute, Plano, Texas.
J Interv Cardiol. 2018 Feb;31(1):68-73. doi: 10.1111/joic.12476. Epub 2017 Dec 28.
Evaluate the role of balloon aortic valvuloplasty (BAV) in improving candidacy of patients for transcatheter aortic valve replacement (TAVR).
Patients who are not candidates for TAVR may undergo BAV to improve functional and clinical status.
117 inoperable or high-risk patients with critical aortic stenosis underwent BAV as a bridge-to-decision for TAVR. Frailty measures including gait speed, serum albumin, hand grip, activities of daily living (ADL); and NYHA functional class before and after BAV were compared.
Mean age was 81.6 ± 8.5 years and the mean Society of Thoracic Surgeons predicted risk of mortality was 9.57 ± 5.51, with 19/117 (16.2%) patients non-ambulatory. There was no significant change in mean GS post-BAV, but all non-ambulatory patients completed GS testing at follow-up. Albumin and hand grip did not change after BAV, but there was a significant improvement in mean ADL score (4.85 ± 1.41 baseline to 5.20 ± 1.17, P = 0.021). The number of patients with Class IV congestive heart failure (CHF) was significantly lower post BAV (71/117 [60.7%] baseline versus 18/117 [15.4%], P = 0.008). 78/117 (66.7%) of patients were referred to definitive valve therapy after BAV.
When evaluating frailty measures post BAV, we saw no significant improvement in mean GS, however, we observed a significant improvement in non-ambulatory patients and ADL scores. We also describe improved Class IV CHF symptoms. With this improved health status, the majority of patients underwent subsequent valve therapy, demonstrating that BAV may improve candidacy of patients for TAVR.
评估球囊主动脉瓣成形术(BAV)在改善经导管主动脉瓣置换术(TAVR)患者入选资格方面的作用。
不适合接受TAVR的患者可接受BAV以改善功能和临床状况。
117例无法手术或高危的严重主动脉瓣狭窄患者接受BAV作为TAVR的决策桥梁。比较包括步速、血清白蛋白、握力、日常生活活动能力(ADL)在内的衰弱指标,以及BAV前后的纽约心脏协会(NYHA)心功能分级。
平均年龄为81.6±8.5岁,胸外科医师协会预测的平均死亡率风险为9.57±5.51,19/117(16.2%)患者不能行走。BAV后平均步速无显著变化,但所有不能行走的患者在随访时均完成了步速测试。BAV后白蛋白和握力未改变,但平均ADL评分有显著改善(基线时为4.85±1.41,随访时为5.20±1.17,P = 0.021)。IV级充血性心力衰竭(CHF)患者数量在BAV后显著减少(基线时71/117 [60.7%],随访时18/117 [15.4%],P = 0.008)。78/117(66.7%)的患者在BAV后接受了确定性瓣膜治疗。
在评估BAV后的衰弱指标时,我们发现平均步速无显著改善,然而,我们观察到不能行走的患者和ADL评分有显著改善。我们还描述了IV级CHF症状的改善。随着健康状况的改善,大多数患者接受了后续的瓣膜治疗,表明BAV可能改善患者接受TAVR的入选资格。